Daxor Biotech Blood Volume Innovation Is Rapidly Improving Patient Outcomes
Daxor Corporation (NYSE: DXR ) President and CEO Michael Feldschuh participated in the Benzinga Biotech Small Cap Conference held on March 24, 2021. He provided an overview on Daxor’s business model and growth strategy, including updates on groundbreaking research and product development as well as new prospective medical trials. Daxor Corporation continues to make news with its breakthrough technology focusing on blood volume measurement innovation. The company developed and markets the BVA-100® (blood volume analyzer), the first and only diagnostic blood test cleared by the Food and Drug Administration (FDA). It provides safe, accurate and objective quantifications of blood volume status and composition compared to patient-specific norms for a variety of medical and surgical conditions including heart failure and critical care. The BVA test is administered at the point of care and samples are sent to the lab to be processed. Within 1 hour or less, results are generated. Over 50,000 blood tests have been performed at leading hospitals across the country since its introduction and has been shown to reduce heart failure mortality by over 80% and readmissions by over 56% in peer-reviewed studies confirming that accurate blood volume measurement enhances hospital performance metrics and leads to better patient outcomes.
Daxor Biotech Blood Volume Innovation Is Rapidly Improving Patient Outcomes
Daxor Corporation (NYSE: DXR ) President and CEO Michael Feldschuh participated in the Benzinga Biotech Small Cap Conference held on March 24, 2021. He provided an overview on Daxor’s business model and growth strategy, including updates on groundbreaking research and product development as well as new prospective medical trials. Daxor Corporation continues to make news with its breakthrough technology focusing on blood volume measurement innovation. The company developed and markets the BVA-100® (blood volume analyzer), the first and only diagnostic blood test cleared by the Food and Drug Administration (FDA). It provides safe, accurate and objective quantifications of blood volume status and composition compared to patient-specific norms for a variety of medical and surgical conditions including heart failure and critical care. The BVA test is administered at the point of care and samples are sent to the lab to be processed. Within 1 hour or less, results are generated. Over 50,000 blood tests have been performed at leading hospitals across the country since its introduction and has been shown to reduce heart failure mortality by over 80% and readmissions by over 56% in peer-reviewed studies confirming that accurate blood volume measurement enhances hospital performance metrics and leads to better patient outcomes.